Just released: The latest podcast episode from Business of Biotech - Summer Executive Sessions discusses how Jeff Wolf, CEO of Heat Biologics, structured the organization and its people in a strategic fashion to support a therapeutic platform. Listen now and subscribe so that you never miss an episode.
By Anna Rose Welch, chief editor, Biosimilar Development
Following publication of his recent white paper, I touched base with Alex Brill to better visualize what a shared savings program might look like for biosimilars and to unpack the questions and challenges facing CMMI in establishing such a program.
Biologics developers and manufacturers demand an accurate and reliable assay for host cell protein (HCP) quantitation. Let’s take a close look at why analytical scientists turn to the ELISA, and how it fits into process development.
Connect + Share: We're coming together in a whole new way. Join us for the GRx+Biosims 2020 Virtual Conference on November 9 to 11, 2020. This year — wherever you are — you can be part of the only online experience for generics and biosimilars professionals. GRx+Biosims is the premier scientific and regulatory event for the U.S. generics and biosimilars industries, featuring timely programming relevant to technical, regulatory, and policy professionals. Hear from top-in-their-field officials and subject matter experts, share knowledge and best practices, and gain insights on navigating the regulatory process approvals and the evolving policy landscape. Register Now.